The Animal Cancer Center at Colorado State University has the following ongoing clinical trial for Hemangiosarcoma:


Patient Disease:
Canine Hemangiosarcoma

Study Name:
Hemangiosarcoma Vaccine Study Purpose of the study:
The purpose of this study is two-fold. First: to determine if stimulating a patient's immune system in a very specific way with one of two new vaccines will prolong survival times in dogs with hemangiosarcoma. Both of the investigational vaccines contain potent immune stimulating factors. Also, the study is intended to determine if this specific immune system stimulation will inhibit new blood vessel formation in the tumor environment. One of the two investigational vaccines contains cells designed to activate the patient's immune system against newly forming tumor blood vessels.
Patient Entry Criteria:                
In general, these studies are available to qualifying patients living within 100 miles of the Animal Cancer Center at Colorado Sate University. The patient must have the disease of hemangiosarcoma, which has been confirmed by biopsy. The disease may not have spread to any other area of the body. In order to qualify for this study, treatment prior to presentation to the Animal Cancer Center must have been very limited. The patient is not to have received radiation therapy, any chemotherapy, or any holistic medical treatment for hemangiosarcoma prior to entry into the study. The patient must not have received steroids (like prednisone) for three weeks before presentation. No other medical conditions may be present that might limit the patient’s life.   And no additional medication may be given once the patient is enrolled into the study. For more information regarding entry criteria, please contact our Consult Coordinator at 970-297-4195.
Owner Responsibilities:
After the initial diagnostic visit, the client is required to bring the patient to regularly scheduled visits for treatment and evaluation for up to a year. The client must allow a total of three skin biopsies to be taken (one pre-treatment and two during treatment) to assess the patient’s response to the vaccination treatment. The patient will receive Adriamycin® chemotherapy every two weeks for a course of five treatments. Additionally, the patient will receive a total of eight vaccine injections; one injection at each chemotherapy treatment, and monthly injections after the completed course of chemotherapy for three consecutive months. No additional medication may be given once the patient is enrolled into the study.    Financial Incentives:
The owner pays for the initial diagnostic work up, usually $400 to $500. The study pays for all treatment visits and for all evaluation recheck visits for a period of one year. For more information regarding financial incentives, please contact our Consult Coordinator at 970-297-4195.

The University of Pennsylvania, Department of Clinical Studies has this available:

Canine Hemangiosarcoma

Efficacy and toxicity of intracavitary Doxil in canine hemangiosarcoma:
The purpose of this study is to evaluate the effectiveness of and toxicities associated with intracavitary administration of Doxil chemotherapy following surgery to dogs with  splenic hemangiosarcoma. Hemangiosarcoma is an aggressive malignancy and the spleen is the most common primary site for this tumor to occur. Most dogs present initially with acute signs associated with tumor rupture, seeding and bleeding into the abdominal cavity. Furthermore, the abdominal cavity is also the main site of tumor recurrence, and most dogs will die or be euthanized due to complications associated with progressive tumor growth within the abdominal cavity. Current standard treatment for dogs with hemangiosarcoma is surgery and systemic (intravenous) doxorubicin-based chemotherapy. Despite the most effective available treatments for this disease, most dogs will succumb to their tumor, and the average survival is approximately 6 months.

Owners of dogs that have been diagnosed with stage 2 or 3 splenic hemangiosarcomas are eligible to enroll their pets in this study after their pets have had their spleens removed surgically (splenectomy).  Enrollment of pets must be completed within 3 weeks of surgery.  Only splenectomized dogs that have had no prior chemotherapy, including doxorubicin, and those without medical problems that contraindicate the use of doxorubicin-based chemotherapy will be eligible.

Please make an appointment with the oncology service or contact the oncology service  for further information if your dog is eligible to participate in this study.

Department of Clinical Studies, Philadelphia
215.898.6678 Office Phone / Voice Mail
215.573.8183 Office Fax
csphil-info@vet.upenn.edu General Information Email



1. J Vet Intern Med. 2000 Sep-Oct;14(5):479-85.

Treatment of canine hemangiosarcoma: 2000 and beyond

Clifford CA, Mackin AJ, Henry CJ.

University of Pennsylvania, Veterinary Teaching Hospital, School of Veterinary Medicine, Philadelphia, PA, USA.

Canine hemangiosarcoma (HSA) is an aggressive and malignant neoplasia with a grave prognosis. Surgery and chemotherapy have limited success in prolonging survival times and increasing quality of life in dogs with HSA. Advances in medical oncology are resulting in increased survival rates and a better quality of life for veterinary cancer patients. An understanding of mechanisms of metastasis has led to the development of new treatments designed to delay or inhibit tumor spread. Promising new treatment options include novel delivery systems (inhalation or intracavitary chemotherapy); use of immunomodulators such as liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine; antimetastatic agents such as inhibitors of angiogenesis (interferons, thalidomide), matrix metalloproteinase inhibitors, and minocycline; dietary modifications; and gene therapy. Inhibitors of angiogenesis seem to be safe and, unlike conventional chemotherapy, do not induce drug resistance. Although many of the newer approaches are still under development and review, the use of multimodality therapy incorporating innovative treatment modalities may offer the best therapeutic option for dogs affected with HSA.